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Abstract
Aims and Background: Model-based insulin sensitivity testing via the
intravenous glucose tolerance test (IVGTT) or similar is clinically very
intensive due to the need for frequent sampling to accurately capture the
dynamics of insulin secretion and clearance. The goal of this study is to
significantly reduce the number of samples required in intravenous glu-
cose tolerance test protocols to accurately identify C-Peptide and insulin
secretion characteristics.
Methods: Frequently sampled, intravenous glucose tolerance test (IVGTT)
data from 12 subjects (5 Normal Glucose Tolerant (NGT), 7 Type 2 Di-
abetes (T2D)) are analyzed to calculate insulin and C-Peptide secretion
using a well-accepted C-Peptide model. Samples are reduced in a series
of steps based on the critical IVGTT profile points required for accurate
estimation of C-Peptide secretion. The full data set of 23 measurements
is reduced to sets with 6 or 4 measurements. Peak secretion rate and to-
tal secreted C-peptide during 10 and 20 minutes post glucose input, and
during the total test time are calculated. Results are compared to those
from the full data set Wilcoxon Rank Sum to assess any differences.
Results: In each case, the calculated secretion metrics are largely un-
changed, within expected assay variation, and not significantly differ-
ent from the results obtained using the full 23 measurement data set
(P < 0.05).
Conclusions: Peak and total C-peptide and insulin secretory character-
istics can be accurately estimated in an IVGTT from as few as 4 system-
atically chosen samples, providing an opportunity to minimize sampling,
cost, and burden.
Keywords: Insulin, C-Peptide, secretion, IVGTT
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1 Introduction
Assessing pancreatic insulin secretion is important in the diagnosis and moni-
toring of type-2 diabetes [1–4]. Different tests and markers have been proposed
to quantify pre-hepatic insulin secretion. These tests include intravenous tests,
such as the hyperglycaemic clamp [5] and the IVGTT [6], oral tests like the
OGTT [2, 7], and fasting state assessments [8, 9]. They also vary in resolution
and the range of information provided, with the intravenous tests generally pro-
viding more details about the bi-phasic secretory characteristics [2].
Good estimation of pre-hepatic insulin secretion can be achieved by estimat-
ing C-peptide secretion through modelling of its kinetics [10–14]. This approach
is unbiased by first pass hepatic extraction of insulin and is a valid marker due
to the equimolar secretion of both peptides [11]. A two compartment model
initially proposed by Eaton et al. [11] has been shown to accurately repre-
sent C-peptide kinetics. To avoid individual model parameter estimation, Van
Cauter et al. [12] proposed a regression model to calculate population param-
eters from known subject specific characteristics, such as height, weight, age,
gender and diagnosis of diabetes. This population methodology has been vali-
dated in several studies with peak errors of 10 %− 20 % [12, 15–17].
Accurate estimation of peak secretion rate and total first phase secreted in-
sulin (first 10 minutes) is currently only possible with very frequent sampling
during this interval. However, precisely capturing the peak C-peptide concen-
tration and timing is crucial for accurate assessment. Especially given the rel-
atively fast first phase secretion dynamics. Frequent sampling protocols during
an IVGTT or similar test, sample C-peptide up to every minute, making these
protocols burdensome to the patient, and difficult and costly to perform, as well
as requiring significant blood sampling.
For a method to be useful in a clinical diagnostic setting, simplicity, robust-
ness and cost of the protocol are important factors. In this study, a simple
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method to estimate C-peptide secretion is proposed, using integrals instead of
a typical deconvolution approach. Furthermore, errors introduced by reduced
sampling are assessed by comparing different reduced sampling approaches to
the full, original frequently sampled data set estimations and values. The anal-
ysis is performed on frequently sampled C-peptide data during an IVGTT in
five Normal Glucose Tolerant (NGT) and seven subjects with Type 2 Diabetes
(T2D).
2 Subjects, Materials and Methods
The C-peptide data from IVGTT studies in this research have been kindly pro-
vided by Dr. Andrea Mari (Institute of Biomedical Engineering, Padova, Italy)
and Dr. Angelo Avogaro (Department of Clinical and Experimental Medicine,
University of Padova, Italy). The data have been previously published [18], with
full description of subjects and experimental protocol. The critical aspects are
briefly reproduced here for clarity.
2.1 Subjects
The study was performed on 12 subjects, 5 with normal glucose tolerance (NGT,
age 24 ± 2, weight 73 ± 6 kg, fasting glucose 5.2 ± 0.1 mmol/l, fasting insulin
50±5 pmol/l) and 7 with type 2 diabtes (T2D, age 49±5, weight 81±3 kg, fasting
glucose 8.6 ± 0.8 mmol/l, fasting insulin 125 ± 27 pmol/l). Pharmacological
treatment in T2D was stopped 3 days before the study and all subjects received
a 2000 kcal/day diet (50% carbohydrate, 35% fat, 15% protein) for at least 30
days prior to the study.
2.2 Experimental Protocol
An insulin-modified IVGTT was performed on all subjects in the morning after
an overnight fast. After three fasting samples at -30, -15 and 0 min, a 0.3 g/kg
glucose bolus was injected. At 20 minutes, insulin was infused for 5 minutes,
totalling 0.03 U/kg (NGT) and 0.05 U/kg (T2D). Blood samples were collected
4
at 2, 3, 4, 5, 6, 8, 10, 15, 20, 25, 30, 40, 60, 80, 100, 120, 140, 160, 180, 210, and
240 min, and analyzed for C-peptide, glucose and insulin concentrations. Only
the C-peptide samples are of interest in this study.
2.3 C-peptide model
A well accepted two compartment model of C-peptide kinetics is employed, as
initially described by Eaton et al. [11]. The equations describing the mass
transport between compartments are defined:
C˙(t) = −(k1 + k3)C(t) + k2Y (t) + S(t)
VC
(1)
Y˙ (t) = k1C(t)− k2Y (t) (2)
where C(t) is the concentrations in the central (or plasma) compartment (pmol/l),
Y (t) is the concentration in the peripheral (or interstitial) compartment (pmol/l),
k1 and k2 are transport rates between the compartments (1/min), k3 is the re-
nal loss from the central compartments (1/min), S(t) is the pancreatic secretion
rate (pmol/min), and VC is the central distribution volume (l). A-priori iden-
tification of the kinetic parameters is done with known subject information, as
described by Van Cauter et al. [12], which is a well utilized, validated and
accurate methodology [15–17].
2.4 Integral-based estimation of C-peptide secretion
Estimation of C-peptide secretion rate S(t) is performed with an integral-based
method, previously employed in real-time parameter identification in glycemic
control trials in the critically ill [19–21] and related biomedical applications.
To best compute the integrals in all time steps, the profile of C-peptide is ap-
proximated using linear interpolation between data points, which introduces no
additional error over model error [21]. The integral functions also have the ad-
5
vantage of being robust to noise in the measured data, effectively providing a
low-pass filter in the summations involved in numerical integrations [21].
C-peptide secretion rate, S(t), is estimated as a step function, with stepsize
of 1 min. Thus, during any given 1 min time interval t ∈ [t0, t1 = t0 + 1], S(t)
is assumed constant. Integrating Equation 1 in the interval [t0, t1] yields:
∫ t1
t0
C˙(t)dt = −(k1 + k3)
∫ t1
t0
C(t)dt+ k2
∫ t1
t0
Y (t)dt+
1
VC
∫ t1
t0
S(t)dt (3)
Solving Equation 2 analytically for Y (t) yields:
Y (t) =
∫ t
0
Cest(τ)e−k2(t−τ)dτ (4)
where Cest represents the interpolated C-peptide values estimated from the dis-
crete sampled measurements. Combining Equations 3 and 4 and solving for the
assumed constant secretion rate S0,1 in this time interval yields:
S0,1 · t1 − t0
VC
= Cest(t1)− Cest(t0) + (k1 + k3)
∫ t1
t0
Cest(t)dt
−k2
∫ t1
t0
∫ t
0
Cest(τ)e−k2(t−τ)dτdt (5)
Repeating this process for the intervals [t1, t2], [t2, t3] etc, results in a 1-min
stepwise constant secretion profile S(t). This estimated S(t) profile is (physi-
ologically) constrained to be non-negative. Smoothing the estimated stepwise
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constant profile with a zero-phase 3-point moving average is done to avoid over-
fitting to noisy data and interpolated measurements [21]. This particular filter
was picked as a simple choice that does not require further assumptions and
does not introduce a phase lag. This last step is not required in frequently
sampled data, but results in a more physiological profile between more sparsely
sampled data.
2.5 Points of discontinuity
To minimize the number of samples required to describe secretion character-
istics, it is crucial to identify key points of physiological discontinuity in the
C-peptide concentration profile. These points of discontinuity are caused by
sudden changes in C-peptide concentration due to either endogenous or ex-
ogenous input. Common changes in C-Peptide secretion that occur during an
IVGTT are shown in Figure 1 and defined:
1. Injection of glucose (D1): A sudden increase in plasma glucose triggers
a secretion burst of stored insulin (first phase) lasting 5-10 minutes, which
is often reduced or blunted in type-2 diabetes [22, 23]. In the C-peptide
concentration profile this dynamic is seen as a very steep rise immediately
after administration of glucose. As glucose is administered between t = 0
and t = 1minutes, a lag of one minute is chosen here to account for glucose
injection and pancreatic response time.
2. Peak first phase secretion rate (D2): Peak C-peptide secretion rate
determines peak C-peptide concentration during the first 10 min post glu-
cose input. In the concentration profile this point is the maximum value
CPmax, located at tCPmax, assumed between 0-10 minutes.
3. End of first phase/Start of second phase secretion (D3): First
phase secretion ends after approximately 10 minutes. If high glucose con-
centrations persist, pancreatic insulin secretion continues to rise or remains
elevated over basal levels (second phase) [24]. In the concentration profile,
this point can be identified as a local minimum around 10 minutes.
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4. Injection of insulin (D4): A sudden increase in plasma insulin inhibits
pancreatic insulin secretion [24]. This response can be significantly delayed
or not evident in type-2 diabetes [24]. In the concentration profile this
point can be seen as a steepening of the negative slope soon after an
exogenous insulin input.
5. Return to basal secretion rate (D5): This step varies widely in in-
dividuals, but is usually more gradual than the preceding factors. In the
concentration profile this change is evident when the slopes are tending
towards zero and the C-peptide concentrations return to fasting values.
To pick a clear point in the curve, this study uses the time of the first
value to reach the fasting level.
All five of these points are typically very pronounced and consistent in
healthy individuals, but can be very gradual, blunted or non-existent in in-
dividuals with diabetes, who have an impaired first phase secretion and often
have delays in pancreatic response to glucose and insulin concentration changes.
Figure 1 shows examples for NGT and T2D subjects with the identified points
of discontinuity. Note that points D2, D3 and D5 can be very variable in differ-
ent individuals and may introduce errors when generic points are chosen.
2.6 Minimal sampling options
The minimal sample optimization analysis is performed in 5 steps. The original
complete data set (Step 1) is the reference to which all of the following steps or
simplifications are compared to assess any loss in accuracy or utility. This full
data set consists of 23 samples.
Steps 2 and 3 are sample-reduced to keep only the optimal median points
of discontinuity identified in NGT (Step 2) and T2D (Step 3) subjects. These
two reduced sets require only 6 samples. The points of discontinuity chosen are
the median time point values observed over all subjects in the data set utilized.
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Figure 1: Example of points of discontinuity identified in the C-peptide profile
during an IVGTT in NGT (top) and T2D (bottom) subjects. The time axis in
T2D is not to scale between 100-240 min.
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Using these median values over this diverse data set creates a generic approach
that will generalize or extrapolate to any similar data set or study.
Step 4 analyzes a further reduction to 4 samples. This set thus keeps only
the most critical points for identifying the dynamics. Specifically, the peak and
the return to basal points.
Whereas Steps 1-4 keep the maximal C-peptide sample (D2)during the first
phase response, Step 5 assesses a different approach. More specifically, it is a
method that does not rely on exactly capturing the peak concentration. The
first sample taken is the sample 2-3 minutes after the median peak time observed
over all subjects. To correct for the missing peak sample and timing, an esti-
mated ’correction’ sample is introduced at 3 minutes. This estimated point is
given a value 10% larger than the actual sample taken 2-3 minutes later. Thus,
this estimated value is used to increase the area under the concentration curve
to a more physiological value without having to capture it explicitly. Note that
while the timing of 3 minutes works well in the data used in this study, this
might not be the case for all people and could be a potential source of error. Its
validity would have to be assessed in a larger validation study.
These five steps are further clarified in Figure 2 and summarized:
• Step 1: Original data set without reduction of samples.
• Step 2: Optimized for NGT subjects. 6 Samples atD1, tCPmax, D3, D4, D5, tend.
• Step 3: Optimized for T2D subjects. 6 Samples atD1, tCPmax, D3, D4, D5, tend.
• Step 4: Further reduction of samples to only include most critical points.
4 Samples at D1, tCPmax, D5, tend.
• Step 5: Sampling missing peak by 2-3 minutes, with ’correction’ sam-
ple introduced at 2 minutes. 6 Samples at D1, (tCPmax − 3), tCPmax +
3, D3, D4, D5, tend.
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Figure 2: Sample optimization Steps 1-5 and samples used for the calculations
in each step. Real samples are marked as ’x’, the introduced ’correction’ sample
in Step 5 is marked with a circle.
The results from each are compared to Step 1 to assess the performance of these
reduced sampling schemes in comparison to the original data set.
2.7 Performance metrics
The performance metrics used in this study try to capture all possible secretory
characteristics of interest. The goal is to assess possible errors introduced by a
reduced sampling protocol. These metrics are defined:
1. First phase peak secretion rate (Smax) and timing of peak (tpeak):
Missing samples in the first minutes after glucose input can lead to large
errors in the estimated peak secretion rate due to a slower observed in-
crease in C-peptide concentration than actually occurs.
2. Total C-peptide secreted in first phase, 0-10 min (AUC10): The
area under curve (AUC), or also described as acute insulin response (AIR),
is a common metric to describe total insulin secreted during first phase
response [2, 9]. It is calculated by integrating estimated secretion rate
between 0-10 minutes.
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3. Total C-peptide secreted between glucose and insulin inputs,
0-20 min (AUC20): As the exogenous insulin inhibits pancreatic insulin
secretion, it could be of interest to assess the endogenously secreted insulin
until it is inhibited by exogenous insulin.
4. Total C-peptide secreted during the IVGTT (AUCtotal): Calcu-
lated by integrating over the complete test, this metric assesses total pan-
creatic effort.
C-Peptide assays also introduce errors for any data set that will affect the
outcome values assessed. These expected error ranges are assessed by Monte
Carlo analysis of the estimated secretion rate (104 runs), employing normally
distributed, zero-mean noise with a coefficient of variation (CV) of 3%. This CV
matches currently reported state of the art assays ([25]), and is thus a conserva-
tive choice, as older radio immunoassays have CV’s of up to twice this value [26],
which would result in larger allowable errors from the reduced sampling protocol.
Therefore, the Monte Carlo analysis provides an expected variation for the
full set of Step 1 due to assay error. Reduced sampling schemes with results
within this assay error range of the Step 1 results would be considered not
different. The use of a small, state of the art CV thus restricts this allowable
variation to a minimum value.
2.8 Statistical analysis
Non-parametric hypothesis testing with the Wilcoxon Rank Sum test is used
to assess if Steps 2-5 are significantly different to Step 1. Normality of results
is assessed by the single sample Kolmogorov-Smirnov (KS) test. Where results
were log-normally distributed, the log-normal geometric mean and multiplica-
tive standard deviation [27] are used, and specifically noted in the respective
results presented.
12
Table 1: Integral method performance compared to metrics obtained by Mari
[18] using a deconvolution approach on the same data. ISRb is basal secretion
rate, ISR1 mean secretion rate over basal in the 6 minutes post glucose injection,
ISR2 mean secretion rate over basal from 7 minutes until glucose reaches basal
levels. Values from this study are converted to match units used by Mari [18].
ISRb ISR1 ISR2
Mean (SEM) in pmol · min−1· m−2
NGT
Deconvolution 71 (7) 900 (233) 127 (37)
Integral method 71 (10) 851 (216) 132 (25)
Correlation (P<0.001) 0.93 1.00 0.95
T2D
Deconvolution 141 (29) 218 (120) 121 (31)
Integral method 136 (30) 277 (136) 130 (34)
Correlation (P<0.001) 0.98 1.00 0.99
3 Results
Pre-hepatic insulin secretion rate was estimated well with the full data set using
the integral-based method, resulting in the stepwise constant profiles in Figure 3.
The qualitative shape of the secretory curves compare well to the clinical data
in the original publication [18]. Mean peak secretion rate is slightly higher in
this study for both subgroups, likely due to the smaller stepsize (1 minute vs.
2 minutes) for the estimated secretion rate fitting in this study. Performance of
the presented integral method is equivalent to the deconvolution method used
by Mari [18], as can be seen by the matching metrics shown in Table 1.
Points of discontinuity are partly given by the protocol, as the timing of
glucose and insulin inputs (D1 = 1 min), and are otherwise identified from the
sampled C-peptide profile in each subject (D2, D3, D4, D5). All identified points
13
are given in Table 2. More variability in all points and especially a distinct lag
in D4 (response to insulin input) and D5 (return to basal) are evident in T2D
subjects, as expected.
Resulting deviations in performance metrics for Steps 2-5, compared to the
original sample sets, are shown in Table 3. None of the metrics in Steps 2-4 were
significantly different to the corresponding reference metrics in Step 1 in both
subgroups (all P < 0.05). The distribution of the resulting performance metrics
is log-normal and results are thus given using log-normal statistics. Relative
differences are normally distributed and are described using normal statistics.
Correlations of Steps 2-5 compared to Step 1 are also shown in Table 3.
Errors in performance metrics due to assay errors were assessed by Monte
Carlo analysis (104 runs) and are given as a CV for each metric, with the median
and 100% range over all 12 subjects:
• Smax: CV=5.47 %, range 2.97− 11.01 %
• AUC10: CV=4.10 %, range 1.92− 9.39 %
• AUC20: CV=3.13 %, range 1.90− 4.26 %
• AUCtotal: CV=1.11 %, range 0.97− 1.25 %
Reconstruction of C-peptide concentrations from the identified secretion pro-
files during the analyzed steps resulted in the residuals shown in Figure 4. Resid-
uals are given as relative values (decimal percentages), compared to the complete
sampling protocol of Step 1. Deviations from the original sample set are caused
by smoothing of the estimated secretion profile, by errors introduced through
linear interpolation and, obviously, by the reduced number of sampling steps
being examined. The ideal goal is to have all variation within the dashed lines
due to assay error.
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Table 2: Points of discontinuity identified in all subjects. Note that points
D2−D5 have significant differences between subgroups. The median values are
used in the generic selection of points for reduced sample analysis to enable a
generalizable approach.
Subject D1 D2 D3 D4 D5
NGT
7 1 4 10 20 100
8 1 4 10 25 60
9 1 3 10 25 80
10 1 3 8 25 60
11 1 4 10 25 80
median 1 4 10 25 80
SD 0.00 0.55 0.89 2.24 16.73
T2D
1 1 3 10 60 240
2 1 6 8 60 160
3 1 2 8 30 100
4 1 2 15 25 240
5 1 4 8 40 180
6 1 2 8 40 120
12 1 3 10 20 240
median 1 3 8 40 180
SD 0.00 1.46 2.57 15.92 59.36
Overall
median 1 3 10 25 100
SD 0.00 1.15 1.98 14.22 71.07
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Table 3: Outcomes of sample reduction steps. Shown are the relative percentile changes
of Steps 2-5 compared to the reference Step 1 (tpeak is given as absolute difference in min).
Results from Step 1 have a log-normal distribution and are described by the log-normal ge-
ometric mean (geom) and the multiplicative standard deviation (multipl). Relative changes
in Steps 2-5 are normally distributed and are described by the mean and standard deviation
(SD). Correlations shown are Steps 2-5 compared to Step 1 (P < 0.001).
Steps (# samples) 1 (23) 2 (6) 3 (6) 4 (4) 5 (6)
Reference Percentile change [%]
NGT
Smax mean (geom) 2578.8 mean -5.52 -7.58 -5.52 -1.80
[pmol/min] SD (multipl) 1.8 SD 1.61 5.68 1.59 5.27
correlation 1.00 0.99 1.00 1.00
tpeak median 3 median 0 0 0 0
[min] SD 0.0 SD 0.0 0.0 0.0 0
AUC10 mean (geom) 10301.8 mean -5.21 2.23 10.10 -0.71
[pmol] SD (multipl) 1.8 SD 1.56 3.10 9.28 2.243
correlation 1.00 1.00 0.99 1.00
AUC20 mean (geom) 15110.8 mean -3.24 -0.54 8.40 -0.62
[pmol] SD (multipl) 1.7 SD 9.97 9.84 9.34 9.56
correlation 0.97 0.97 0.97 0.97
AUCtotal mean (geom) 42648.9 mean 4.95 19.44 9.30 5.70
[pmol] SD (multipl) 1.4 SD 4.42 6.53 3.98 3.76
correlation 0.99 0.99 1.00 1.00
T2D
Smax mean (geom) 826.3 mean -15.64 -2.36 -15.30 -0.61
[pmol/min] SD (multipl) 2.5 SD 14.32 12.07 13.91 21.47
correlation 1.00 1.00 1.00 0.96
tpeak median 3 median 0 0 0 0
[min] SD 0.8 SD 0.8 0.8 3.0 1.11
AUC10 mean (geom) 4600.7 mean -6.40 -0.73 5.42 -2.39
[pmol] SD (multipl) 2.5 SD 5.83 9.27 27.14 10.88
correlation 1.00 1.00 0.99 1.00
AUC20 mean (geom) 9439.8 mean -4.23 -4.47 -6.76 -2.23
[pmol] SD (multipl) 2.4 SD 9.38 12.74 20.27 8.66
correlation 0.99 0.98 0.95 0.99
AUCtotal mean (geom) 82523.7 mean 0.43 -0.52 -1.32 0.63
[pmol] SD (multipl) 2.2 SD 5.18 4.36 6.21 5.39
correlation 1.00 1.00 1.00 1.00
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Figure 4: Residuals introduced when reproducing the full C-peptide sample
profile with the sample reduction steps. The solid line shows the mean residuals
and the grey area shows the full 100 % range of residuals in that step. The
dashed lines show the 95 % range of residuals for Step 1 (full sample set) that
is introduced by assay error, as estimated by Monte Carlo analysis.
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4 Discussion
Estimating pre-hepatic insulin secretion through modelling of C-peptide kinet-
ics has been a common methodology and is relatively less-invasive to perform
in research settings [12–14, 28]. In particular, the population method proposed
by Van Cauter et al. [12] enables the estimation of secretion rate with a sin-
gle experiment. By employing this method, model parameters are consistent
across studies, enabling a better comparison, as tradeoffs between estimated
parameters and secretion rates are reduced. Nonetheless, the estimation of
peak secretion rate and insulin secreted during first phase is still highly depen-
dent on assay errors and sampling frequency during the initial minutes. Ideally,
sampling should be performed every minute to assess an accurate profile, which
introduces significant labor, cost, and burden, as well as reducing the robustness
of the method.
It is important to keep in mind that significant errors are also introduced due
to assay inaccuracy. Thus, for example, peak estimated secretion rate, Smax,
has a median CV= 5.47 % and can therefore vary between ±11 % (±2 σ), even
with a 1-minute step sampling protocol. Most of the performance metrics are
within, or slightly outside of ±2 σ of assay error. This result implies that they
are, in fact, just within the natural variability that can be identified [26].
Using the same model and Van Cauter et al.’s parameter estimation method,
estimation of secretion rate has previously been proposed by deconvolution [11]
and a more elaborate constrained regularization method [14]. The main draw-
backs of these methods are the individualized method adjustments required for
each subject, including knot placements for cubic spline interpolations [11], or a
separate step to find the optimal proportionality constant in each subject [14].
All of these extra steps introduce time, computation and human variability into
the results. While criteria are available to determine optimal regularization
parameters, such as Maximum Likelihood, these methods require underlying
a-priori assumptions about the parameter solutions and thus add complexity to
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the approach.
In contrast, the integral-based method described in this study is a single
step, computationally convex and fast method that only requires linearly inter-
polated data. By constraining the resulting linear least squares estimation to
non-zero values and smoothing the estimated secretion rate, the resulting profile
is physiologically accurate and the effects caused by noisy data are reduced [21].
First and second phase secretion characteristics were clearly identified, with
slight quantitative, but not qualitative, deviations from the profiles originally
reported with this data by Mari [18]. In addition, these smaller deviations can
be readily explained by the longer stepsize used in that study. In a quantita-
tive comparison, the secretion metrics obtained with the integral-based method
compare very well to the secretion metrics calculated by Mari [18] using a de-
convolution method, as seen in Table 1. Correlations of the subgroup results
are all very high, showing equality in performance of both methods when the
full sample data set is used.
The reduction of samples was approached by identifying key points of dis-
continuity and reducing the sample set to those points. Points of discontinuity
varied only slightly during first phase secretion in both subgroups, but were
significantly delayed in T2D during the second secretion phase. This delay can
be attributed to a delay in pancreatic response to insulin input in the case of
D4 [24] and an increased total demand and production rate during this stage,
in D5 [1].
Comparing Steps 2 and 3, which are optimized for the NGT and T2D sub-
groups respectively, it can be seen that maximum secretion rate Smax is more
accurate in the subgroup for which it was optimized. This result is especially
valid for the T2D subjects in Step 3. This result also holds is for total secreted
C-peptide AUCtotal in NGT and T2D, but is not the case in the other metrics.
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The standard deviations of the metrics are mostly very broad in T2D, espe-
cially in the metrics during the first minutes. This result indicates a very broad
variability in the estimated metric. This variability may be due in part to the
strongly blunted first phase response in T2D, resulting in a weak signal to noise
ratio and thus exaggerating the effects of assay errors. Nonetheless, none of the
sample reduced steps were statistically significantly different than the reference
Step 1 (P < 0.05).
As can be seen in the residuals reported in Figure 4, Step 2 has a clear ad-
vantage over Step 3 in NGT subjects. In T2D subjects a slight advantage for
Step 3 is evident between 0-20 minutes, but the remaining time is equivalent to
Step 2. This behavior could be due to the fact that the points of discontinuity
in the time after insulin input are not as distinct in T2D, and thus not as critical
if inaccurately chosen. Larger residuals appear after t = 20 minutes in all cases,
where sampling is less frequent. During the first section up to t = 20 minutes,
residuals are mostly within the assay variation bounds shown for the full sample
set (Step 1), giving accurate estimations of the most dynamic secretory char-
acteristics. Overall, Step 2 seems to be the better choice if one generic setting
were chosen for both types of subjects examined.
In Step 4, where samples are further reduced to a total of 4, residuals are
more variable, but still within similarly tight ranges, as in the previous steps.
In particular, the first phase section is well represented and captured. In NGT
subjects, residuals are even tighter than in Step 3, which has two additional
samples that are not optimally placed for this group.
Finally, Step 5 analyzes a different approach by introducing a calculated
’correction’ sample to make up for the missing concentration peak sample. This
step appears to give the tightest residuals during the first phase, even tighter
than the full sampling set. This unexpected result is due to a more accurate fast
rise in concentration, as the sample is introduced at t = 2 minutes, resulting
21
in a higher secretory peak. Without this correction sample, linear interpolation
from 1-6 minutes would result in a far slower secretion rate increase and a more
constant and non-physiological estimated secretion rate during these initial 5
minutes. Hence, the resulting area under the concentration curve is more phys-
iological, which results in a more accurate integrated secretion curve and thus
better residuals. During the later phase of these tests, the residuals are identical
to Step 2 because the same sample timings are used.
Overall, it can be seen that reduced sampling does not necessarily compro-
mise the information that can be gathered from such a test. This is clearly
visible by the very high correlations shown in Table 3 between the full and the
sample reduced steps. However, smart sample placement is critical and needs
to be chosen correctly according to the secretory information of interest to the
researcher. Steps 2 and 3 propose optimized sampling protocols for NGT and
T2D subgroups respectively, enabling the investigator to decide on an optimal
sampling schedule when designing a test protocol. Even a heavily reduced and
generic protocol using only 4 (17%) of the original 23 samples (Step 4), results
in acceptable accuracy in the stated performance metrics, most of which are
still within reported assay errors.
While the methods developed in this study performed well on the presented
dataset, it could be argued that the number of subjects is insufficient to validate
the approach. We acknowledge that the number of subjects used to derive the
presented method is limited. The goal of the study was not to clinically vali-
date the method, but to derive and present a new method to estimate insulin
secretion, that is more robust and automated compared to previously presented
methods. In that sense, it should be regarded as a pilot study to derive a new
method. This new method would have to be validated in a separate study on
a different dataset to prove its validity. In addition, the use of physiologically
relevant points of discontinuity that are readily recognizable and well-accepted
adds weight to the underlying assumption that the results of this limited pilot
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analysis would carry through in a larger study.
In a similar approach, the analysis presented in this study could also be
applied to a C-peptide dataset without insulin administration. New points of
discontinuity would have to be defined as they could differ slightly, particularly
around the time when insulin is administered. We believe that the approach
would work just as well on such a dataset, but it is out of the scope of this study
to analyze different trial protocols. This could be analyzed in a separate study
with a corresponding dataset.
We believe that our approach is novel compared to other methods to esti-
mate insulin secretion presented in the past. Strong emphasis was placed on
developing a robust and convex method that would allow automated analysis
of C-peptide data without requiring manual intervention or a-priori assump-
tions about the solutions. While methods presented in the past have primarily
focused on accuracy on full data sets, our approach has been primarily on a
method that could be applied to reduced data sets and thus be more useful in
routine clinical testing environments, where time and cost contribute greatly to
the success of a test.
5 Conclusions
Estimation of pre-hepatic insulin or C-peptide secretion can be achieved using
an easy to apply population model in combination with a simple and consistent
integral-based deconvolution method. Reduction of samples to reduce test com-
plexity, clinical burden, and cost can be done without significantly reducing the
accuracy of the test. If smart sample placements are chosen by identifying key
points of discontinuity these reductions are readily enabled, saving significant
cost and burden.
The approaches presented in this study include sampling optimized for NGT
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or T2D subjects (6 samples), a further reduction to 4 samples, and a final option
that does not require samples during the first 5 minutes after glucose adminis-
tration by introducing an additional calculated ’correction’ sample. Each step
further reduces the sampling stress, cost and blood taken. Overall, the results
show that reduced sampling has no clinical or research "cost" in the outcome
metrics derived, as shown by Monte Carlo and statistical results, but can enable
significantly simpler test protocols.
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